BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 26744318)

  • 1. MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.
    Zhang B; Zhao R; He Y; Fu X; Fu L; Zhu Z; Fu L; Dong JT
    Oncotarget; 2016 Feb; 7(5):5702-14. PubMed ID: 26744318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3,6-Dihydroxyflavone Suppresses Breast Carcinogenesis by Epigenetically Regulating miR-34a and miR-21.
    Peng X; Chang H; Gu Y; Chen J; Yi L; Xie Q; Zhu J; Zhang Q; Mi M
    Cancer Prev Res (Phila); 2015 Jun; 8(6):509-17. PubMed ID: 25784176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long noncoding RNA MEG3 suppresses cell proliferation, migration and invasion, induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells.
    Zhu M; Wang F; Mi H; Li L; Wang J; Han M; Gu Y
    Cell Cycle; 2020 Dec; 19(23):3277-3288. PubMed ID: 33121324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BMP-6 inhibits cell proliferation by targeting microRNA-192 in breast cancer.
    Hu F; Meng X; Tong Q; Liang L; Xiang R; Zhu T; Yang S
    Biochim Biophys Acta; 2013 Dec; 1832(12):2379-90. PubMed ID: 24012720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-199a-3p regulates endometrial cancer cell proliferation by targeting mammalian target of rapamycin (mTOR).
    Wu D; Huang HJ; He CN; Wang KY
    Int J Gynecol Cancer; 2013 Sep; 23(7):1191-7. PubMed ID: 23851675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
    Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
    Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Xu K; Yagüe E
    Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.
    Zheng P; Dong L; Zhang B; Dai J; Zhang Y; Wang Y; Qin S
    Histochem Cell Biol; 2019 Oct; 152(4):281-291. PubMed ID: 31352515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
    Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.
    Chu J; Zhu Y; Liu Y; Sun L; Lv X; Wu Y; Hu P; Su F; Gong C; Song E; Liu B; Liu Q
    Oncotarget; 2015 Oct; 6(31):31944-57. PubMed ID: 26397135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential altered expression of let-7a and miR-205 tumor-suppressor miRNAs in different subtypes of breast cancer under treatment with Taxol.
    Asghari F; Haghnavaz N; Shanehbandi D; Khaze V; Baradaran B; Kazemi T
    Adv Clin Exp Med; 2018 Jul; 27(7):941-945. PubMed ID: 30019863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
    Qian XJ; Li YT; Yu Y; Yang F; Deng R; Ji J; Jiao L; Li X; Wu RY; Chen WD; Feng GK; Zhu XF
    Oncotarget; 2015 Mar; 6(7):5134-46. PubMed ID: 25762617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
    PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1.
    Wang R; Zhang T; Yang Z; Jiang C; Seng J
    J Cell Mol Med; 2018 Sep; 22(9):4068-4075. PubMed ID: 29971911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo.
    Chen SY; Hu SS; Dong Q; Cai JX; Zhang WP; Sun JY; Wang TT; Xie J; He HR; Xing JF; Lu J; Dong YL
    Asian Pac J Cancer Prev; 2013; 14(10):6135-40. PubMed ID: 24289639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing Aurora A leads to re-sensitization of breast cancer cells to Taxol through downregulation of SRC-mediated ERK and mTOR pathways.
    Li Y; Zhou W; Tang K; Chen X; Feng Z; Chen J
    Oncol Rep; 2017 Oct; 38(4):2011-2022. PubMed ID: 28849180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-424-5p enhances chemosensitivity of breast cancer cells to Taxol and regulates cell cycle, apoptosis, and proliferation.
    Dastmalchi N; Safaralizadeh R; Hosseinpourfeizi MA; Baradaran B; Khojasteh SMB
    Mol Biol Rep; 2021 Feb; 48(2):1345-1357. PubMed ID: 33555529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression.
    Hu Y; Zhu Q; Tang L
    PLoS One; 2014; 9(3):e92099. PubMed ID: 24637915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-129-3p promotes docetaxel resistance of breast cancer cells via CP110 inhibition.
    Zhang Y; Wang Y; Wei Y; Li M; Yu S; Ye M; Zhang H; Chen S; Liu W; Zhang J
    Sci Rep; 2015 Oct; 5():15424. PubMed ID: 26487539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.